Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness

Sponsor
Manhattan Psychiatric Center (Other)
Overall Status
Completed
CT.gov ID
NCT00661869
Collaborator
Eli Lilly and Company (Industry)
295
1
1
16
18.4

Study Details

Study Description

Brief Summary

Obesity is increasing at an alarming rate in patients with schizophrenia, possibly in association with the increased use of atypical antipsychotics. In order to address the weight and metabolic syndrome issues, Manhattan Psychiatric Center (MPC) has implemented the Solutions for Wellness and Team Solutions Program. This program is designed to create a supportive, educational and monitoring environment to stabilize both the psychiatric and medical conditions and to prepare patients for independent management of their psychiatric and physical health condition in the community.

Condition or Disease Intervention/Treatment Phase
  • Other: Wellness Program
N/A

Detailed Description

The present program is divided into five detailed segments with three progressive levels, that provide a manualized lesson-by-lesson curriculum for implementation on the treatment mall.

  • Medication Education

  • Symptom recognition and management

  • Living Healthy

  • Interpersonal Skills

  • Discharge Preparation

The program comprised of detailed instructor and patient manuals, specific curriculums and pre- and post-tests to determine acquisition of the learned materials. All modules are imbedded in weekly small group sessions.

  • Each of the 5 modules are discussed in groups in weekly morning or afternoon session, Monday through Friday.

  • Each module is divided into three 12-week periods for a total of 36 sessions.

  • Upon completing 12 weeks at Level 1, each patient moves to Level 2 and then Level 3 for 12 weeks each.

  • Each group has two trained instructors.

  • Number of patients per group: ≤ 15.

  • Sessions are interspersed within the patient's regular treatment mall classes

Study Design

Study Type:
Interventional
Actual Enrollment :
295 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness
Study Start Date :
Sep 1, 2006
Actual Primary Completion Date :
Sep 1, 2007
Actual Study Completion Date :
Jan 1, 2008

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Wellness Group

Other: Wellness Program
36 weeks of educational and supportive interventions

Outcome Measures

Primary Outcome Measures

  1. Pre and post-test knowledge assessments attained from each module [36 weeks]

  2. Change in weight, abdominal girth, blood pressure, metabolic markers (Glucose , Insulin, C-peptide, Glycohemoglobin, total cholesterol, total triglycerides, HDL and LDL, leptin, and free fatty acid (FFA)) [36 weeks]

Secondary Outcome Measures

  1. Systolic and diastolic blood pressure [36 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Are at lease 18 years of age; ≤ 65 years.

  2. Are male or female

  3. Are currently hospitalized at Manhattan Psychiatric Center and attend daily treatment mall programs.

  4. Are fluent in the language of the investigator, and study staff (including testing administrators, group leaders and supervisors)

  5. Have a documented current psychiatric diagnosis as obtained from patient's medical charts and recorded by a qualified psychiatrist.

  6. Recently admitted patients will be included if their clinical state permits it.

Exclusion Criteria:
  1. Are > 65 years of age;

  2. Are currently enrolled in the Intensive Psychiatric Services (IPS) program at Manhattan Psychiatric Center;

Contacts and Locations

Locations

Site City State Country Postal Code
1 Manhattan Psychiatric Center New York New York United States 10035

Sponsors and Collaborators

  • Manhattan Psychiatric Center
  • Eli Lilly and Company

Investigators

  • Principal Investigator: Jean-Pierre Lindenmayer, M.D., New York University School of Medicine & Manhattan Psychaitric Center

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00661869
Other Study ID Numbers:
  • 05I/C51-3
First Posted:
Apr 21, 2008
Last Update Posted:
Aug 9, 2010
Last Verified:
Aug 1, 2010

Study Results

No Results Posted as of Aug 9, 2010